[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contrast-induced-acute-kidney-injury-in-st-segment-elevation-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contrast-induced-acute-kidney-injury-in-st-segment-elevation-myocardial-infarction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100651528","the-effect-of-hydration-on-the-prevention-of-ci-aki-in-stemi-patients-undergoing-primary-pci-hydro-aki-trial-100651528",false,"NCT07761754","The Effect of Hydration on the Prevention of CI-AKI in STEMI Patients Undergoing Primary PCI (Hydro-AKI Trial)","The Effect of Hydration on the Prevention of Contrast Induced Acute Kidney Injury (CI-AKI) in ST Segment Elevation Myocardial Infarction Undergoing Primary PCI (Hydro-AKI Trial)","Hydro-AKI","Inclusion Criteria:\n\nInclusion Criteria\n\nAll of the following must be present:\n\n* Age ≥18 years at the time of randomization\n* Clinical diagnosis of STEMI, confirmed by 12-lead ECG showing ≥30 minutes of ST-segment elevation ≥1 mm in ≥2 contiguous limb leads or ≥2 mm in ≥2 contiguous precordial leads, or new left bundle branch block with a clinical presentation consistent with acute myocardial infarction\n* Decision to proceed with primary PCI as the reperfusion strategy, within 12 hours of symptom onset (or up to 24 hours if evidence of persistent ischaemia or haemodynamic instability)\n* Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73m², calculated by the CKD-EPI 2021 formula from the most recent available serum creatinine measurement prior to contrast exposure\n* Ability to swallow and safely tolerate oral fluids, as assessed by the attending physician\n* Oral informed consent obtained from the patient or a legally authorized representative (deferred consent protocol applies in emergencies per IRB approval)\n\nExclusion Criteria:\n\n* \\- Cardiogenic shock on presentation, defined as systolic blood pressure \\\u003C90 mmHg for \\>30 minutes despite fluid resuscitation, or requirement for vasopressor or inotropic therapy to maintain SBP ≥90 mmHg, with evidence of end-organ hypoperfusion (Killip Class IV)\n* Acute pulmonary oedema or Killip Class III with SpO₂ \\\u003C90% on room air, bilateral crepitations \\>50% of lung fields, or chest X-ray showing pulmonary venous congestion requiring urgent diuresis\n* Pre-existing dialysis dependence (haemodialysis or peritoneal dialysis) or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² on admission\n* Active vomiting, dysphagia, altered consciousness (GCS \\\u003C14), or any clinical condition precluding safe oral fluid intake, as assessed by the attending physician\n* Administration of any IV hydration protocol for CIN prevention prior to randomization (patients may have received standard IV fluids for other indications; these are documented but do not constitute exclusion unless specifically intended as CIN prophylaxis)\n* Known severe allergy to iodinated contrast media that cannot be managed with pre-medication (moderate\u002Fmild allergies and prior mild reactions are not exclusions)\n* Concurrent administration of known nephrotoxic agents within 48 hours that cannot be withheld or dose-adjusted: aminoglycoside antibiotics (gentamicin, amikacin), high-dose loop diuretics in the context of diuretic nephropathy, or cisplatin-based chemotherapy\n* Pregnancy (confirmed by urine or serum beta-hCG) or active breastfeeding\n* Estimated life expectancy \\\u003C30 days from a non-cardiac cause (advanced malignancy, end-stage liver disease, multiorgan failure)","ALL","18 Years",{"count":20,"type":21},384,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine whether a structured oral hydration regimen reduces the incidence of contrast-induced acute kidney injury (CI-AKI) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). The main questions it aims to answer are:\n\nDoes a structured oral hydration regimen reduce the incidence of CI-AKI compared with standard care without a prescribed hydration regimen? Does oral hydration improve renal outcomes without increasing the risk of adverse events, such as heart failure or fluid overload, in patients undergoing PPCI?\n\nResearchers will compare patients receiving a structured oral hydration regimen with patients receiving standard care without a prescribed hydration regimen to determine whether oral hydration decreases the incidence of CI-AKI and improves clinical outcomes.\n\nParticipants will:\n\nBe randomly assigned to either the oral hydration group or the standard care group.\n\nUndergo primary percutaneous coronary intervention according to institutional practice.\n\nReceive the assigned hydration strategy after the procedure. Have serum creatinine measured at baseline and after contrast exposure to assess for CI-AKI.\n\nBe monitored for adverse events, including fluid overload, heart failure, need for renal replacement therapy, length of hospital stay, and other relevant clinical outcomes.",[27,28],"Contrast-Induced Acute Kidney Injury in ST-Segment Elevation Myocardial Infarction","Contrast Induced AKI","NOT_YET_RECRUITING","2026-08-15",{"date":32,"type":33},"2026-08-18","ACTUAL",{"date":35,"type":21},"2026-08",{"date":37,"type":21},"2029-06",{"name":39,"class":40},"Assiut University","OTHER"]